喹硫平与氟哌啶醇治疗活动型谵妄:随机对照试验
本研究为随机对照试验,纳入100例诊断为活动型谵妄的成人ICU患者,随机接受口服喹硫平(25-50 mg/日)或氟哌啶醇(1-2 mg/日)。主要终点为应答,定义为DRS-R-98严重程度评分较基线下降≥50%且DRS-R-98严重程度评分≤12且无复发。总体应答率为92%,两组应答率相当(p=0.609)。次要终点中,两组ICU死亡率(p=0.496)、院内死亡率(p=0.321)、住院时间(p=0.310)和机械通气需求(p>0.99)相当;但喹硫平组平均ICU住院时间缩短(10.1±2.0 vs 11.7±2.6天,p=0.018),夜间睡眠时间增加(p=0.001)。结论认为喹硫平治疗重症患者活动型谵妄症状可能等效于氟哌啶醇,无死亡获益。
要点
- 100例活动型谵妄成人ICU患者随机接受口服喹硫平25-50 mg/日或氟哌啶醇1-2 mg/日,总体应答率92%,两组应答率相当(p=0.609)。
- 喹硫平组平均ICU住院时间较氟哌啶醇组缩短(10.1±2.0 vs 11.7±2.6天,p=0.018)。
- 喹硫平组夜间睡眠时间较氟哌啶醇组增加(p=0.001)。
- 两组ICU死亡率(p=0.496)、院内死亡率(p=0.321)、住院时间(p=0.310)和机械通气需求(p>0.99)无显著差异。
- 作者认为喹硫平治疗活动型谵妄症状可能等效于氟哌啶醇,无死亡获益。
适用人群与场景
- 成人ICU患者,诊断为活动型谵妄,共100例随机分组。
诊断标准与关键阈值
- 活动型谵妄诊断基于原文未详述的临床标准。
- 应答定义:DRS-R-98严重程度评分较基线下降≥50%且DRS-R-98严重程度评分≤12且无复发。
处置流程与药物剂量
- 口服喹硫平25-50 mg/日。
- 口服氟哌啶醇1-2 mg/日。
研究设计与关键结果
- 随机对照试验,纳入100例成人ICU活动型谵妄患者,随机接受口服喹硫平25-50 mg/日或氟哌啶醇1-2 mg/日。
- 总体应答率92%,两组应答率相当(p=0.609)。
- 喹硫平组平均ICU住院时间10.1±2.0天 vs 氟哌啶醇组11.7±2.6天(p=0.018)。
- 喹硫平组夜间睡眠时间增加(p=0.001)。
- 两组ICU死亡率(p=0.496)、院内死亡率(p=0.321)、住院时间(p=0.310)和机械通气需求(p>0.99)无显著差异。
- 全部患者平均年龄68±6岁。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ICU活动型谵妄成人患者,口服喹硫平25-50 mg/日与氟哌啶醇1-2 mg/日相比,总体应答率相当,但喹硫平组ICU住院时间更短、夜间睡眠时间更长;作者认为喹硫平可能等效于氟哌啶醇,无死亡获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In the population of patients in the intensive care unit (ICU), most studies compared the use of atypical antipsychotics, such as quetiapine, with the use of traditional haloperidol in patients with delirium of various forms and etiologies. The role of such agents in patients with hyperactive delirium is not fully understood. This study compares the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on the Delirium Rating Scale-Revised-98 (DRS-R-98), length of stay in the ICU, and mortality in critically ill patients.
METHODS: One hundred adult patients diagnosed with hyperactive delirium were randomly assigned to receive either oral quetiapine (25-50 mg/day) or haloperidol (1-2 mg/day). The response, defined as "a DRS-R-98 severity score reduction from baseline of 50% or more" and a DRS-R-98 severity score of 12 or less without relapse, was the primary outcome.
RESULTS: The mean age of all patients was 68 ± 6 years. The study population's overall response rate was 92%. Response rates for the two groups were remarkably equal (p = 0.609). Secondary outcomes were comparable in both groups, such as ICU mortality (p = 0.496), in-hospital mortality (p = 0.321), in-hospital stay (p = 0.310), and the need for mechanical ventilation (p > 0.99). But the quetiapine group showed a statistically reduced mean ICU stay (10.1 ± 2.0 vs. 11.7 ± 2.6 days, p = 0.018) and increased sleeping hours per night (p = 0.001).
CONCLUSIONS: Quetiapine may be equally as effective as haloperidol in treating the symptoms of hyperactive delirium in critically ill patients, with no mortality benefit.
参考来源
- Zakhary T, Ahmed I, Luttfi I, et al. Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium: Randomized Controlled Trial. Neurocrit Care. 2024. PMID: 38561588. doi:10.1007/s12028-024-01948-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。